undamentalytics Newsletter

Johnson & Johnson insider trading

Every open-market purchase and sale by Johnson & Johnson's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
Johnson & Johnson insider open-market trades
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Johnson & Johnson’s insiders pay?

From February 12, 2010 to September 4, 2026, 35 insiders reported 18 open-market purchases and 124 sales not made under a pre-set plan in Johnson & Johnson. Twelve months after each purchase was reported, the shares were −3.9% against the S&P 500 on average (median −5.8%), over 17 purchases with a full year of prices; 35% beat the index. After sales, the shares moved −4.9% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 16, 2010 into $56,139 by November 2, 2026, +10.9% a year. It held shares 53% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $41,784 (+8.9% a year), and held throughout $92,597 (+14.3%).

$0$50.0k$100k 201020122014201620182020202220242026 $92.6k$56.1k$41.8k
Copying Johnson & Johnson's insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Johnson & Johnson's insiders from February 16, 2010, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 53% of the time.
Johnson & Johnson: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Fasolo Peter Exec VP, Chief HR Officer 0 — — 15 −18.0% (15) July 27, 2023
Perez William D Director 9 −11.2% (9) 22% 0 — March 17, 2020
Kapusta Ronald A Controller, CAO 0 — — 8 −7.1% (8) December 14, 2018
Caruso Dominic J Exec VP, Finance; CFO 0 — — 7 −1.8% (7) July 24, 2017
Cullen James Director 0 — — 7 −0.7% (7) September 11, 2014
Decker Robert J VP Corporate Controller 0 — — 7 +1.5% (6) March 3, 2026
Cosgrove Stephen J Corporate Controller 0 — — 6 −1.7% (6) November 7, 2014
Deyo Russell C VP, General Counsel 0 — — 6 +3.8% (6) February 23, 2012
Duato Joaquin CEO and Chairman of the Board 0 — — 6 +0.4% (3) August 14, 2026
Stoffels Paulus Exec VP, Chief Scientific Off 0 — — 6 −2.2% (6) February 20, 2018
Wengel Kathryn E EVP, Chief TO and Risk Officer 0 — — 6 −21.1% (5) June 12, 2026
Weldon William C Chairman/CEO 0 — — 5 +4.3% (5) September 11, 2012
Mongon Thibaut Exec VP, WW Chair, Consumer 0 — — 4 −10.2% (4) November 8, 2022
Prince Charles Director 4 +7.2% (4) 75% 0 — December 17, 2018
Schmid Timothy EVP, WW Chair, MedTech 0 — — 4 +43.2% (1) September 4, 2026
Sneed Michael E EVP, Global Corp Aff & COO 0 — — 4 −12.6% (4) December 10, 2020
Taubert Jennifer L EVP, WWC. Innovative Medicine 0 — — 4 −4.7% (3) August 18, 2026
Ullmann Michael H Exec VP, General Counsel 0 — — 4 −2.0% (4) February 3, 2017
Wolk Joseph J Exec VP, CFO 0 — — 4 +15.6% (3) February 18, 2026
Broadhurst Vanessa EVP, Global Corp Affairs 0 — — 3 −3.9% (1) July 21, 2026
Hait William See Remarks 0 — — 3 −19.5% (3) July 27, 2023
Reed John C EVP, Innovative Medicine, R&D 0 — — 3 +33.4% (2) February 18, 2026
Mccoy Sherilyn S Member, Executive Committee 0 — — 2 −0.7% (2) November 17, 2011
Mcevoy Ashley EVP, WW Chair, MedTech 0 — — 2 −21.1% (2) December 2, 2022
Pruden Gary J Exec VP, WW Chair, Med Devices 0 — — 2 −5.7% (2) March 2, 2017
Swanson James D. EVP, CIO 0 — — 2 −22.7% (1) February 18, 2026
Forminard Elizabeth EVP, Chief Legal Officer 0 — — 1 — August 7, 2026
Goggins Colleen A Member, Executive Committee 0 — — 1 +2.1% (1) September 13, 2010
Gorsky Alex Chairman, CEO 0 — — 1 −23.2% (1) November 16, 2018
Hewson Marillyn A Director 1 −4.2% (1) 0% 0 — June 11, 2019
Joly Hubert Director 1 −11.0% (1) 0% 0 — December 16, 2019
Lindquist Susan L Director 0 — — 1 +7.6% (1) December 10, 2012
Morikis John G Director 1 — — 0 — December 1, 2025
Mulcahy Anne M Director 1 −14.9% (1) 0% 0 — December 17, 2018
Weinberger Mark A Director 1 +35.4% (1) 100% 0 — December 12, 2024

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Johnson & Johnson

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Johnson & Johnson in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −9.1% against the index. After 16 selling crowds, −3.3%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
August 31, 20265 sellingnot yetnot yetnot yet
February 27, 20266 selling−19.4%−3.7%not yet
August 29, 20253 selling+11.3%+34.8%+37.1%
February 28, 20253 selling−4.6%−0.1%+37.8%
July 31, 20233 selling−2.5%−11.8%−24.8%
November 30, 20226 selling−12.4%−16.4%−22.7%
April 29, 20223 selling−3.1%+3.0%−7.5%
February 28, 20203 selling+8.1%−3.5%−12.3%
February 28, 20193 buying−3.2%−9.1%−7.2%
November 30, 20184 selling−5.9%−11.0%−18.5%
March 31, 20175 selling+3.8%−1.9%−7.0%
July 29, 20163 selling−5.7%−14.4%−7.1%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Latest 12 of 18. Total returns from the month end; past patterns are not a forecast.

← Back to Johnson & Johnson · Funds · Politicians